Sonia Gregory | Scientific Leader
GSK Vaccines

Sonia Gregory, Scientific Leader, GSK Vaccines

Dr. Sonia Gregory leads the Self Amplifying mRNA (SAM) CMC Platform team at GSK Vaccines, which is focused on process and product improvement, scale up, analytical strategy, QbD, rapid response, and acceleration of RNA products. She earned a BS and MS in Chemistry from the University of North Carolina Wilmington and a PhD in Biophysics from the University of Virginia. Sonia identified lead therapeutic molecules for progression into development using biophysical techniques at Merck and later transitioned into Technical Development at Novartis Vaccines now GSK Vaccines, where SAM originated. At GSK she has been a lead contributor on key programs where she optimized formulations, process development, and scale-up processes to enable meeting program milestones and clinical manufacture.

Appearances:



Day 3, September 30th @ 13:40

Interactive panel: Unique rapid production opportunities and challenges that face nucleic acid-based vaccine manufacture and delivery

  • Why and where will it make a difference?
  • How is it different to DNA vaccines?
  • What are the unique challenges and advantages of RNA vaccine?
  • How will RNA vaccines help in an outbreak like SARS-CoV-2? Can the scale-up/volume be big enough?
  • Does the speed and dosage have an effect on the overall quality of the vaccine?
last published: 24/Sep/20 10:05 GMT
last published: 24/Sep/20 10:05 GMT
last published: 24/Sep/20 10:05 GMT
last published: 24/Sep/20 10:05 GMT
last published: 24/Sep/20 10:05 GMT
last published: 24/Sep/20 10:05 GMT
last published: 24/Sep/20 10:05 GMT
last published: 24/Sep/20 10:05 GMT
last published: 24/Sep/20 10:06 GMT
last published: 24/Sep/20 10:06 GMT

back to speakers